Navegação Artigos de Periódicos por Assunto "Azitromicina"
Resultados 1-6 de 6
-
Acute generalized exanthematous pustulosis during puerperal period induced by azithromycin : case report
(2018) [Artigo de periódico]Background: The use of antibiotics, especially beta-lactams and macrolides, may be associated with dermatopathies, such as Acute Generalized Exanthematous Pustulosis (AGEP), which is an uncommon cutaneous adverse reaction. ... -
Antibiotic therapy for pelvic inflammatory disease
(2017) [Artigo de periódico]Background Pelvic inflammatory disease (PID) is an infection that affects 4% to 12% of young women, and is one of the most common causes of morbidity in this age group. The main intervention for acute PID is the use of ... -
Comparação entre a azitromicina e a amoxicilina no tratamento da exacerbação infecciosa da doença pulmonar obstrutiva crônica
(2007) [Artigo de periódico]Objetivo: Comparar a eficácia, segurança e tolerabilidade da azitromicina e da amoxicilina no tratamento de pacientes com quadro clínico de exacerbação infecciosa da doença pulmonar obstrutiva crônica. Métodos: Seis centros ... -
Efficacy of azithromycin and miltefosine in experimental systemic pythiosis in immunosuppressed mice
(2019) [Artigo de periódico]We evaluated the efficacy of azithromycin (50 mg/kg, every 12 h [q12h] orally) and miltefosine (25 mg/kg, q24h orally) treatments in an experimental model of vascular/disseminated pythiosis in immunosuppressed mice. ... -
Photo-mediated and advanced oxidative processes applied for the treatment of effluents with drugs used for the treatment of early COVID-19 : review
(2021) [Artigo de periódico]The COVID-19 pandemic is proving to be one of the most challenging health and social crises ever faced by humanity. Several drugs have been proposed as potential antiviral agents for the treatment of COVID-19 since the ... -
Sales of "COVID kit" drugs and adverse drug reactions reported by the Brazilian Health Regulatory Agency
(2022) [Artigo de periódico]Off-label use of azithromycin, hydroxychloroquine, and ivermectin (the "COVID kit") has been suggested for COVID-19 treatment in Brazil without clinical or scientific evidence of efficacy. These drugs have known adverse ...